Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.21
CHE's Cash to Debt is ranked higher than
67% of the 240 Companies
in the Global Medical Care industry.

( Industry Median: 0.23 vs. CHE: 0.21 )
CHE' s 10-Year Cash to Debt Range
Min: 0   Max: 2.78
Current: 0.21

0
2.78
Equity to Asset 0.51
CHE's Equity to Asset is ranked higher than
77% of the 232 Companies
in the Global Medical Care industry.

( Industry Median: 0.45 vs. CHE: 0.51 )
CHE' s 10-Year Equity to Asset Range
Min: 0.31   Max: 0.61
Current: 0.51

0.31
0.61
Interest Coverage 8.87
CHE's Interest Coverage is ranked higher than
80% of the 154 Companies
in the Global Medical Care industry.

( Industry Median: 5.49 vs. CHE: 8.87 )
CHE' s 10-Year Interest Coverage Range
Min: 1.85   Max: 12
Current: 8.87

1.85
12
F-Score: 6
Z-Score: 5.37
M-Score: -2.89
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 9.44
CHE's Operating margin (%) is ranked higher than
76% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 9.44 vs. CHE: 9.44 )
CHE' s 10-Year Operating margin (%) Range
Min: -2.6   Max: 11.56
Current: 9.44

-2.6
11.56
Net-margin (%) 5.46
CHE's Net-margin (%) is ranked higher than
78% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 4.97 vs. CHE: 5.46 )
CHE' s 10-Year Net-margin (%) Range
Min: -3.61   Max: 10.72
Current: 5.46

-3.61
10.72
ROE (%) 17.20
CHE's ROE (%) is ranked higher than
93% of the 227 Companies
in the Global Medical Care industry.

( Industry Median: 8.44 vs. CHE: 17.20 )
CHE' s 10-Year ROE (%) Range
Min: -5.85   Max: 20.78
Current: 17.2

-5.85
20.78
ROA (%) 8.64
CHE's ROA (%) is ranked higher than
92% of the 235 Companies
in the Global Medical Care industry.

( Industry Median: 3.63 vs. CHE: 8.64 )
CHE' s 10-Year ROA (%) Range
Min: -3.02   Max: 10.8
Current: 8.64

-3.02
10.8
ROC (Joel Greenblatt) (%) 143.50
CHE's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 16.84 vs. CHE: 143.50 )
CHE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -14.36   Max: 185.32
Current: 143.5

-14.36
185.32
Revenue Growth (%) 11.00
CHE's Revenue Growth (%) is ranked higher than
85% of the 200 Companies
in the Global Medical Care industry.

( Industry Median: 7.00 vs. CHE: 11.00 )
CHE' s 10-Year Revenue Growth (%) Range
Min: -18.9   Max: 42.9
Current: 11

-18.9
42.9
EBITDA Growth (%) 6.70
CHE's EBITDA Growth (%) is ranked higher than
74% of the 171 Companies
in the Global Medical Care industry.

( Industry Median: 6.80 vs. CHE: 6.70 )
CHE' s 10-Year EBITDA Growth (%) Range
Min: -31.3   Max: 52.3
Current: 6.7

-31.3
52.3
EPS Growth (%) 5.40
CHE's EPS Growth (%) is ranked higher than
68% of the 153 Companies
in the Global Medical Care industry.

( Industry Median: 10.90 vs. CHE: 5.40 )
CHE' s 10-Year EPS Growth (%) Range
Min: -15.4   Max: 56.8
Current: 5.4

-15.4
56.8
» CHE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

CHE Guru Trades in Q2 2013

Paul Tudor Jones 4,900 sh (New)
Steven Cohen 87,652 sh (New)
Joel Greenblatt 149,723 sh (+67.94%)
John Keeley 23,510 sh (+20.94%)
Mario Gabelli 859,903 sh (+10.62%)
Jim Simons Sold Out
Chuck Royce 1,412,670 sh (-0.67%)
» More
Q3 2013

CHE Guru Trades in Q3 2013

Richard Pzena 360,943 sh (New)
Joel Greenblatt 243,527 sh (+62.65%)
John Keeley 27,010 sh (+14.89%)
Mario Gabelli 875,633 sh (+1.83%)
Chuck Royce 1,413,195 sh (+0.04%)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
Q4 2013

CHE Guru Trades in Q4 2013

John Hussman 61,000 sh (New)
Joel Greenblatt 274,224 sh (+12.61%)
John Keeley 28,910 sh (+7.03%)
Chuck Royce 1,443,220 sh (+2.12%)
Mario Gabelli 881,698 sh (+0.69%)
Richard Pzena 362,343 sh (+0.39%)
» More
Q1 2014

CHE Guru Trades in Q1 2014

David Dreman 565 sh (New)
Jeremy Grantham 33,147 sh (New)
Jim Simons 39,219 sh (New)
Joel Greenblatt 295,553 sh (+7.78%)
Chuck Royce 1,504,885 sh (+4.27%)
John Hussman 61,000 sh (unchged)
Richard Pzena 347,051 sh (-4.22%)
Mario Gabelli 823,015 sh (-6.66%)
John Keeley 22,500 sh (-22.17%)
» More
» Details

Insider Trades

Latest Guru Trades with CHE

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Keeley 2014-03-31 Reduce -22.17%0.01%$73.31 - $88.81 $ 97.2720%22500
David Dreman 2014-03-31 New Buy$73.31 - $88.81 $ 97.2720%565
John Hussman 2013-12-31 New Buy0.33%$66.14 - $79.93 $ 97.2732%61000
Joel Greenblatt 2013-09-30 Add 62.65%0.22%$66.04 - $75.88 $ 97.2737%243527
Joel Greenblatt 2013-06-30 Add 67.94%0.19%$63.9 - $81.79 $ 97.2733%149723
John Keeley 2013-06-30 Add 20.94%0.01%$63.9 - $81.79 $ 97.2733%23510
John Keeley 2012-06-30 Add 45.36%0.01%$54.78 - $64.06 $ 97.2764%17240
Joel Greenblatt 2012-03-31 Add 41.49%0.13%$51.18 - $63.87 $ 97.2778%84545
Ron Baron 2012-03-31 Sold Out 0.12%$51.18 - $63.87 $ 97.2778%0
John Keeley 2012-03-31 Add 44.81%$51.18 - $63.87 $ 97.2778%11860
Joel Greenblatt 2011-12-31 Add 110.65%0.19%$48.24 - $60.68 $ 97.2782%59753
Ron Baron 2011-12-31 Reduce -50.18%0.14%$48.24 - $60.68 $ 97.2782%371627
John Keeley 2011-12-31 New Buy0.01%$48.24 - $60.68 $ 97.2782%8190
Joel Greenblatt 2011-09-30 Add 131.33%0.14%$50.64 - $67.08 $ 97.2766%28366
Joel Greenblatt 2011-06-30 Add 65.9%0.04%$63.94 - $72.02 $ 97.2744%12262
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Chemed Corp

Mario Gabelli Comments on Chemed Corp. - Jan 29, 2014

Chemed Corp. (CHE)(0.3%) (CHE - $76.62 - NYSE) , based in Cincinnati, OH, is a holding company that owns the Vitas hospice company and the Roto Rooter plumbing business. Vitas is the nation's largest hospice company, with almost $1 billion in annual sales. The company is currently facing headwinds from government billing changes and a regulatory investigation, but its management is working hard to protect margins and it should begin to move beyond these issues in 2014. Roto Rooter is enjoying steady revenue growth and record profitability as the economy, particularly the housing market, improves. With strong free cash flow and modest capital expenditures, Chemed is returning the vast majority of its cash flow to shareholders via significant share repurchases.

 

From Mario Gabelli (Trades, Portfolio)’s Gabelli Asset Fund fourth quarter 2013 commentary.

Check out Mario Gabelli latest stock trades

Top Ranked Articles about Chemed Corp

Mario Gabelli Comments on Chemed Corp.
Chemed Corp. (CHE)(0.3%) (CHE - $76.62 - NYSE) , based in Cincinnati, OH, is a holding company that owns the Vitas hospice company and the Roto Rooter plumbing business. Vitas is the nation's largest hospice company, with almost $1 billion in annual sales. The company is currently facing headwinds from government billing changes and a regulatory investigation, but its management is working hard to protect margins and it should begin to move beyond these issues in 2014. Roto Rooter is enjoying steady revenue growth and record profitability as the economy, particularly the housing market, improves. With strong free cash flow and modest capital expenditures, Chemed is returning the vast majority of its cash flow to shareholders via significant share repurchases. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 23.90
CHE's P/E(ttm) is ranked higher than
82% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 39.10 vs. CHE: 23.90 )
CHE' s 10-Year P/E(ttm) Range
Min: 10.7   Max: 41.64
Current: 23.9

10.7
41.64
P/B 3.80
CHE's P/B is ranked higher than
65% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 2.80 vs. CHE: 3.80 )
CHE' s 10-Year P/B Range
Min: 1.63   Max: 5.08
Current: 3.8

1.63
5.08
P/S 1.30
CHE's P/S is ranked higher than
74% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 1.64 vs. CHE: 1.30 )
CHE' s 10-Year P/S Range
Min: 0.67   Max: 2.46
Current: 1.3

0.67
2.46
PFCF 18.50
CHE's PFCF is ranked higher than
83% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 32.98 vs. CHE: 18.50 )
CHE' s 10-Year PFCF Range
Min: 7.11   Max: 47.43
Current: 18.5

7.11
47.43
EV-to-EBIT 14.07
CHE's EV-to-EBIT is ranked higher than
86% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 26.54 vs. CHE: 14.07 )
CHE' s 10-Year EV-to-EBIT Range
Min: 6.9   Max: 124.3
Current: 14.07

6.9
124.3
PEG 2.80
CHE's PEG is ranked higher than
85% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. CHE: 2.80 )
CHE' s 10-Year PEG Range
Min: 0.3   Max: 5.71
Current: 2.8

0.3
5.71
Shiller P/E 24.20
CHE's Shiller P/E is ranked higher than
92% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. CHE: 24.20 )
CHE' s 10-Year Shiller P/E Range
Min: 15.69   Max: 137.8
Current: 24.2

15.69
137.8
Current Ratio 0.59
CHE's Current Ratio is ranked higher than
50% of the 236 Companies
in the Global Medical Care industry.

( Industry Median: 1.40 vs. CHE: 0.59 )
CHE' s 10-Year Current Ratio Range
Min: 0.57   Max: 1.88
Current: 0.59

0.57
1.88
Quick Ratio 0.57
CHE's Quick Ratio is ranked higher than
52% of the 236 Companies
in the Global Medical Care industry.

( Industry Median: 1.24 vs. CHE: 0.57 )
CHE' s 10-Year Quick Ratio Range
Min: 0.56   Max: 1.79
Current: 0.57

0.56
1.79

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.80
CHE's Dividend Yield is ranked lower than
81% of the 144 Companies
in the Global Medical Care industry.

( Industry Median: 1.55 vs. CHE: 0.80 )
CHE' s 10-Year Dividend Yield Range
Min: 0.35   Max: 1.42
Current: 0.8

0.35
1.42
Dividend Payout 0.19
CHE's Dividend Payout is ranked higher than
96% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. CHE: 0.19 )
CHE' s 10-Year Dividend Payout Range
Min: 0.07   Max: 11
Current: 0.19

0.07
11
Dividend growth (3y) 13.50
CHE's Dividend growth (3y) is ranked higher than
84% of the 94 Companies
in the Global Medical Care industry.

( Industry Median: 5.30 vs. CHE: 13.50 )
CHE' s 10-Year Dividend growth (3y) Range
Min: -42.4   Max: 35.7
Current: 13.5

-42.4
35.7
Yield on cost (5-Year) 1.93
CHE's Yield on cost (5-Year) is ranked higher than
52% of the 145 Companies
in the Global Medical Care industry.

( Industry Median: 2.01 vs. CHE: 1.93 )
CHE' s 10-Year Yield on cost (5-Year) Range
Min: 0.85   Max: 3.43
Current: 1.93

0.85
3.43
Share Buyback Rate 6.90
CHE's Share Buyback Rate is ranked higher than
96% of the 176 Companies
in the Global Medical Care industry.

( Industry Median: -1.40 vs. CHE: 6.90 )
CHE' s 10-Year Share Buyback Rate Range
Min: 6.9   Max: -10.2
Current: 6.9

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.10
CHE's Price/DCF (Projected) is ranked higher than
90% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 3.72 vs. CHE: 1.10 )
CHE' s 10-Year Price/DCF (Projected) Range
Min: 0.59   Max: 2.33
Current: 1.1

0.59
2.33
Price/Median PS Value 1.20
CHE's Price/Median PS Value is ranked higher than
72% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 1.27 vs. CHE: 1.20 )
CHE' s 10-Year Price/Median PS Value Range
Min: 0.44   Max: 1.67
Current: 1.2

0.44
1.67
Price/Peter Lynch Fair Value 2.70
CHE's Price/Peter Lynch Fair Value is ranked higher than
87% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. CHE: 2.70 )
CHE' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.51   Max: 5.42
Current: 2.7

0.51
5.42
Earnings Yield (Greenblatt) 7.10
CHE's Earnings Yield (Greenblatt) is ranked higher than
80% of the 225 Companies
in the Global Medical Care industry.

( Industry Median: 5.40 vs. CHE: 7.10 )
CHE' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 14.5
Current: 7.1

0.8
14.5
Forward Rate of Return (Yacktman) 13.27
CHE's Forward Rate of Return (Yacktman) is ranked higher than
80% of the 203 Companies
in the Global Medical Care industry.

( Industry Median: 10.68 vs. CHE: 13.27 )
CHE' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -21.7   Max: 60
Current: 13.27

-21.7
60

Business Description

Industry: Health Care Providers » Medical Care
Compare:FMS, DVA, FSNUY, BDUUF, SKHCY » details
Traded in other countries:CXM.Germany
Chemed Corporation was incorporated in Delaware in 1970 as a subsidiary of W.R. Grace & Co. The Company, through its subsidiaries, operates in the healthcare, and repair and maintenance fields in the United States. Its business is segmented into two - Vitas segment and Roto-Rooter segment. Vitas Healthcare Corporation provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers. The Roto-Rooter provides plumbing and drain cleaning services to both residential and commercial customers. Roto-Rooter has manufacturing and distribution center facilities in West Des Moines, Iowa and has 105 leased and owned office and service facilities in 30 states. Vitas operate 51 programs from 146 leased facilities and 36 inpatient units in 18 states and the District of Columbia.
» More Articles for CHE

Headlines

Articles On GuruFocus.com
Mario Gabelli Comments on Chemed Corp. Jan 29 2014 
The Gabelli Asset Fund Shareholder Commentary - Fourth Quarter 2013 Jan 29 2014 
3 Cheap Health Care Dividend Stocks with Huge Potential to Grow Dividends Oct 02 2013 
comment on CHE May 07 2013 
comment on CHE May 07 2013 
Chemed Corporation: Fundamental Stock Research Analysis Jan 29 2013 
12 Healthcare Dividend Stocks With Highest Short Float Ratio Jun 02 2012 
hospice, roto rooter Jan 11 2012 
9 Dividend Stocks Raising Their Yield On Cost Aug 15 2011 
Guru Stocks Raising Dividends: THO, ACU, KAMN, PRIM, CHE Aug 15 2011 

More From Other Websites
CHEMED CORP Files SEC form 8-K, Results of Operations and Financial Condition Jul 23 2014
Chemed Reports Second-Quarter 2014 Results Jul 23 2014
Q2 2014 Chemed Corporation Earnings Release - After Market Close Jul 23 2014
NYSE stocks posting largest volume increases Jul 22 2014
Chemed To Report Second-Quarter 2014 Earnings July 23rd, Related Conference Call To Be Held On July... Jul 07 2014
Chemed To Report Second-Quarter 2014 Earnings July 23rd, Related Conference Call To Be Held On July... Jul 07 2014
CHEMED CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Jul 02 2014
Chemed Corporation Announces a Five-Year $450 Million Amended and Restated Credit Agreement Jul 01 2014
CHEMED CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 23 2014
Chemed Corporation to Present at the Jefferies 2014 Global Healthcare Conference May 23 2014
Chemed Corporation Holds Annual Meeting of Shareholders; Board Declares Quarterly Dividend May 19 2014
Chemed Corporation to Present at the UBS Global Healthcare Conference May 15 2014
CHEMED CORP Financials May 09 2014
Chemed Corporation to Present at the Bank of America Merrill Lynch 2014 Health Care Conference May 08 2014
CHEMED CORP Files SEC form 10-Q, Quarterly Report May 02 2014
Chemed Corporation to Present at the Deutsche Bank 39th Annual Health Care Conference May 01 2014
Chemed Corporation's CEO Discusses Q1 2014 Results - Earnings Call Transcript Apr 30 2014
Chemed Corporation Earnings Call scheduled for 10:00 am ET today Apr 30 2014
CHEMED CORP Files SEC form 8-K, Results of Operations and Financial Condition Apr 29 2014
Chemed Reports First-Quarter 2014 Results Apr 29 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide